

Anderson Diagnostics supports indigenous development of TataMD Check COVID-19 test

15 May 2021 | News

The kit is based on the Feluda CRISPR technology and has already conducted more than 10000 tests



Anderson Diagnostics, located in Chennai, has collaborated with TataMD to help produce COVID test kits. The partnership is expected to scale test kit production and optimise COVID tests. This, in turn, will help bring down the infection rate.

Anderson Diagnostics announced its partnership with Tata Medical and Diagnostics to support the indigenous development of TataMD Check, a COVID diagnostic kit that is completely developed in India. It is a novel COVID test kit developed based on ICMR guidelines and approved by DGCA.

The kit is based on the Feluda CRISPR technology and has already conducted more than 10000 tests.

Dr. Srinivasaraman, Director, Anderson Diagnostics and Labs, said, "Our collaboration with the Tata MD has helped us clinically support the pandemic by transforming COVID testing."

Girish Krishnamurthy, MD & CEO, Tata Medical and Diagnostics, said, "We are happy to work with the smart and productive team at Anderson Diagnostics. The partnership has strengthened our capacity to produce a technology-based product like TataMD CHECK. The collaboration will drive innovation in the diagnostic space of the pandemic, which will scale the testing capacity in remote areas."